According to astronomical data, Beijing Li Sanhe Ze Biotechnology Co., Ltd., in which the three companies participated, launched a phase I clinical trial of patients with "non-ST-segment elevation acute coronary syndrome (NSTE-ACS)" on 202 1. At present, all the subjects have been treated in the group, and the data of clinical trials are being analyzed and summarized.
Zhongyuan Sheikh Cell Genetic Engineering Co., Ltd. is a life science and technology innovative enterprise with the core vision of developing "precision medicine".